Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and

Abstract:
Cerulean Pharma Inc., a biopharmaceutical company focused on novel, intelligently designed, nanoparticle-based drugs, announced today that Oliver S. Fetzer has been named as President and Chief Executive Officer. He has also been elected to the Company's board of directors. Dr. Fetzer will succeed Alan L. Crane, who has been named Chairman of the board of directors.

Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and

Cambridge, MA | Posted on April 10th, 2009

Dr. Fetzer has a diverse background in biotechnology and healthcare. Most recently, he was Senior Vice President, Corporate Development and Research and Development at Cubist Pharmaceuticals. While at Cubist his responsibilities included Corporate Development, Business Development, Drug Discovery Research, Non-Clinical Development, Clinical Development, Chemical Development, Medical Affairs and Program Management.

Prior to joining Cubist, Oliver served as a Managing Director and Partner at the Boston Consulting Group in the firm's healthcare practice where he was responsible for projects in strategy, operational effectiveness, and mergers and integration.

Dr. Fetzer worked at Bayer AG early in his career where he was involved in chemistry and pharmaceutics. He is a director of Auxilium Pharmaceuticals (NASDAQ: AUXL) and holds a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina and an MBA from Carnegie Mellon University. "I am very excited about joining Cerulean" said Dr. Fetzer. "The opportunity to develop a technology and grow a company with such broad implications for the pharmaceutical industry and to do it with an absolutely world-class team is truly exceptional." "We are extremely pleased that Oliver Fetzer will be assuming the role of CEO at Cerulean," said Alan Crane, Chairman of the board of Cerulean. "As we move our first products towards the clinic and further demonstrate the power of our nanopharmaceutical platform, Oliver's leadership, strategic and operational skills across science and business will be invaluable."

In addition to serving as Chairman of Cerulean, Mr. Crane will assume the role of General Partner at Polaris Venture Partners, where he has been a Venture Partner since 2002.

####

About Cerulean Pharma
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel, nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Millennium Pharmaceuticals, Pfizer, GlaxoSmithKline, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center. The company has been funded by leading investors Polaris Venture Partners, Venrock, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts.

For more information, please click here

Contacts:
Cerulean Pharma, Inc.
161 First Street
Cambridge, MA 02142
Tel 617-551-9600
Fax 617-494-1544

Copyright © Cerulean Pharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Cerulean Pharma

Related News Press

News and information

'Lasers rewired': Scientists find a new way to make nanowire lasers: Berkeley Lab, UC Berkeley scientists adapt next-gen solar cell materials for a different purpose February 12th, 2016

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

Announcements

Graphene leans on glass to advance electronics: Scientists' use of common glass to optimize graphene's electronic properties could improve technologies from flat screens to solar cells February 12th, 2016

Breaking cell barriers with retractable protein nanoneedles: Adapting a bacterial structure, Wyss Institute researchers develop protein actuators that can mechanically puncture cells February 12th, 2016

Replacement of Toxic Antibacterial Agents Possible by Biocompatible Polymeric Nanocomposites February 12th, 2016

Properties of Polymeric Nanofibers Optimized to Treat Damaged Body Tissues February 12th, 2016

Appointments/Promotions/New hires/Resignations/Deaths

NSS Pays Tribute to Late NSS Governor Dr. Marvin Minsky, A Pioneer in Artificial Intelligence February 11th, 2016

Tesla NanoCoatings Gains Talents of Joe Davis as Vice President-Sales Engineer January 27th, 2016

Semblant Appoints Donald Cunningham as Chief Commercial Officer January 2nd, 2016

Beneq introduces new growth strategy and company structure - Jukka Nieminen appointed President December 15th, 2015

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic